Novo Nordisk breaks ground on new plant in Russia
17 April 2012 | By Novo Nordisk
Novo Nordisk broke ground on a new USD 100 million plant that will formulate and fill modern insulin into Novo Nordisk’s Penfill® cartridges...
List view / Grid view
17 April 2012 | By Novo Nordisk
Novo Nordisk broke ground on a new USD 100 million plant that will formulate and fill modern insulin into Novo Nordisk’s Penfill® cartridges...
17 April 2012 | By Tecan
Tecan’s Infinite® M1000 plate reader has enabled researchers at the Institute of Entomology (ENTU)...
17 April 2012 | By Abbott
Statistically significant improvements...
17 April 2012 | By Catalent Pharma Solutions
Norman Weichbrodt, Research & Development Strategic Account Manager for Catalent Pharma Solutions will present “Advanced Aseptic Processing using Blow/Fill/Seal Technology” at Pharma Congress 2012 in Dusseldorf, Germany on Tuesday, April 24, 2012.
16 April 2012 | By Eli Lilly and Company
Lilly Diabetes & Walgreens to help combat the problem of hypoglycemia unawareness...
16 April 2012 | By Catalent Pharma Solutions
Nascent and Catalent announced the signing of a product development agreement...
16 April 2012 | By Karen Taylor PR
Owen Mumford, one of the UK’s largest manufacturers of medical devices has opened its doors for business in China...
New applications improve the efficiency of microbial quality control processes...
16 April 2012 | By Merck
Vintafolide is currently being evaluated in a Phase III clinical trial...
13 April 2012 | By HORIBA Scientific
Bio-Rad’s KnowItAll® Informatics System software offered for use with the HORIBA Scientific range of Raman spectrometers...
13 April 2012 | By HORIBA Scientific
HORIBA Scientific, is proud to announce the organization of a label-free conference, in cooperation with ELSEVIER...
12 April 2012 | By Catalent Pharma Solutions
Dr. Browne & Mr. Meissonnier will present...
Lonza and Agennix AG announced today an agreement for the production of Agennix’s first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI), talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC).
12 April 2012 | By BASF
After acquiring Cognis in 2011, BASF has significantly expanded its range of solubilization and dermatology excipients...
11 April 2012 | By GlaxoSmithKline
GlaxoSmithKline has published its Corporate Responsibility Report...